Abstract
1. The present study examined the effects of the selective 5-HT6 receptor antagonist 4-amino-N-(2, 6 bis-methylamino-pyrimidin-4-yl)-benzene sulphonamide (Ro 04-6790) on locomotor activity and unconditioned behaviour in male Sprague Dawley rats (230-300 g). 2. In non-quantified behavioural observations, animals treated with Ro 04-6790 (3, 10 or 30 mg kg(-1), i.p) showed no overt behavioural signs except a dose-dependent reduction in locomotor activity and a behavioural syndrome of stretching, yawning and chewing. The latter behaviour was most pronounced between 30 and 90 min following the administration of Ro 04-6790. 3. Detailed analysis of the stretching and yawning behaviour showed that Ro 04-6790 (3, 10 or 30 mg kg(-1), i.p.) dose-dependently induced stretching. The number of stretches observed following treatment with either Ro 04-6790 (10 mg kg(-1) i.p.) or Ro-04-6790 (30 mg kg(-1), i.p.) was significantly greater than that observed in saline-treated rats. The yawning behaviour, however, was not dose-dependent nor was the number of yawns in any of the drug treated groups significantly greater than in those treated with saline. 4. Pretreatment (30 min) with the non-selective muscarinic antagonists scopolamine (0.1, 0.3 or 1 mg kg(-1), i.p.) and atropine (0.3, 1 or 3 mg kg(-1), s.c.) but not methylatropine (1, 3 or 10 mg kg(-1), s.c) significantly inhibited stretching induced by Ro 04-6790 (30 mg kg(-1), i.p.). 5. The dopamine D2-like receptor antagonist, haloperidol (0.03, 0.1 or 0.3 mg kg(-1), s.c.) given at the same time as Ro 04-6790 (30 mg kg(-1), i.p.) had no effect on the stretching induced by the 5-HT6 antagonist. 6. These data suggest that systemic injection of the 5-HT6 antagonist, Ro 04-6790, produces a stretching behaviour that appears to be mediated by an increase in cholinergic neurotransmission in the CNS and which could be a useful functional correlate for 5-HT6 receptor blockade. There is no evidence for dopamine D2-like receptor involvement in this behaviour.
MeSH Terms
Acetylcholine/metabolism
Animals
Atropine/pharmacology
Atropine Derivatives/pharmacology
Behavior, Animal/drug effects
Male
Motor Activity/drug effects
Oligonucleotides, Antisense/pharmacology
Pyrimidines/pharmacology
Rats
Rats, Sprague-Dawley
Receptors, Serotonin/drug effects
Scopolamine/pharmacology
Serotonin Antagonists/pharmacology
Yawning/drug effects
Chemicals
Atropine Derivatives
Oligonucleotides, Antisense
Pyrimidines
Receptors, Serotonin
Ro 4-6790
Serotonin Antagonists
serotonin 6 receptor
Atropine
methylatropine
Scopolamine
Acetylcholine
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Bentley J C
Pharma Division, Preclinical Research, F. Hoffmann La Roche Ltd, Basel, Switzerland.
Bourson A
Boess F G
Fone K C
Marsden C A
Petit N
Sleight A J
References (27)
27 references, click to expand
-
The cholinergic hypothesis of geriatric memory dysfunction.
Science. 1982 Jul 30;217(4558):408-14
PMID: 7046051
-
Behavioral effects of ACTH and MSH peptides.
J Endocrinol Invest. 1981 Apr-Jun;4(2):241-51
PMID: 6268695
-
Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides.
Science. 1993 Jan 22;259(5094):528-31
PMID: 8380941
-
Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs.
Mol Pharmacol. 1993 Mar;43(3):320-7
PMID: 7680751
-
Antisense oligodeoxynucleotides to NMDA-R1 receptor channel protect cortical neurons from excitotoxicity and reduce focal ischaemic infarctions.
Nature. 1993 May 20;363(6426):260-3
PMID: 8487863
-
A novel rat serotonin (5-HT6) receptor: molecular cloning, localization and stimulation of cAMP accumulation.
Biochem Biophys Res Commun. 1993 May 28;193(1):268-76
PMID: 8389146
-
In vivo administration of an oligodeoxynucleotide antisense to the D2 dopamine receptor messenger RNA inhibits D2 dopamine receptor-mediated behavior and the expression of D2 dopamine receptors in mouse striatum.
J Pharmacol Exp Ther. 1994 Feb;268(2):1015-23
PMID: 8113958
-
Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors.
J Pharmacol Exp Ther. 1994 Mar;268(3):1403-10
PMID: 7908055
-
Behavioural evidence that different neurochemical mechanisms underly stretching-yawning and penile erection induced in male rats by SND 919, a new selective D2 dopamine receptor agonist.
Psychopharmacology (Berl). 1993;113(2):172-6
PMID: 7855178
-
Localization of serotonin subtype 6 receptor messenger RNA in the rat brain by in situ hybridization histochemistry.
Neuroscience. 1995 Feb;64(4):1105-11
PMID: 7753378
-
Determination of the role of the 5-ht6 receptor in the rat brain: a study using antisense oligonucleotides.
J Pharmacol Exp Ther. 1995 Jul;274(1):173-80
PMID: 7616396
-
Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor.
J Neurochem. 1996 Jan;66(1):47-56
PMID: 8522988
-
Nitric oxide is involved in the ACTH-induced behavioral syndrome.
Peptides. 1995;16(7):1263-8
PMID: 8545248
-
Quantitative RT-PCR distribution of serotonin 5-HT6 receptor mRNA in the central nervous system of control or 5,7-dihydroxytryptamine-treated rats.
Synapse. 1996 Jul;23(3):164-73
PMID: 8807744
-
Immuno-localization of serotonin 5-HT6 receptor-like material in the rat central nervous system.
Brain Res. 1997 Jan 23;746(1-2):207-19
PMID: 9037500
-
5-HT receptor classification and nomenclature: towards a harmonization with the human genome.
Neuropharmacology. 1997 Apr-May;36(4-5):419-28
PMID: 9225265
-
Functional and radioligand binding characterization of rat 5-HT6 receptors stably expressed in HEK293 cells.
Neuropharmacology. 1997 Apr-May;36(4-5):713-20
PMID: 9225298
-
The neuropharmacology of yawning.
Eur J Pharmacol. 1998 Feb 5;343(1):1-16
PMID: 9551709
-
Characterization of Ro 04-6790 and Ro 63-0563: potent and selective antagonists at human and rat 5-HT6 receptors.
Br J Pharmacol. 1998 Jun;124(3):556-62
PMID: 9647481
-
The 5-hydroxytryptamine6 receptor-selective radioligand [3H]Ro 63-0563 labels 5-hydroxytryptamine receptor binding sites in rat and porcine striatum.
Mol Pharmacol. 1998 Sep;54(3):577-83
PMID: 9730917
-
THE IMPORTANCE OF LIPID-SOLUBILITY FOR THE CENTRAL ACTION OF CHOLINOLYTIC DRUGS.
Int J Neuropharmacol. 1965 Jul;4:207-18
PMID: 14343875
-
Behavioral effects induced by intracisternally injected ACTH and MSH.
Ann N Y Acad Sci. 1963 Feb 4;104:330-45
PMID: 13944852
-
Stretching and yawning movements after intracerebral injection of ACTH.
Rev Can Biol. 1967 Sep;26(3):229-36
PMID: 4294515
-
Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse.
Psychopharmacologia. 1968 Sep 20;13(3):222-57
PMID: 5679627
-
Is yawning a cholinergic response?
Nature. 1977 May 19;267(5608):261-2
PMID: 865617
-
Direct evidence for involvement of dopaminergic inhibition and cholinergic activation in yawning.
Psychopharmacology (Berl). 1980 Jan;67(1):39-43
PMID: 6768077
-
Role of calcium in the expression of ACTH-induced stretching, yawning and penile erection.
Brain Res Bull. 1990 Jun;24(6):853-6
PMID: 2372702